Investors seeking direct engagement with emerging life sciences companies will have that opportunity on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the event features seven companies presenting 30-minute live sessions, each followed by audience Q&A. Replays will be available on the B2i Digital and OTC Markets YouTube channels, extending the reach of these presentations beyond the live event.
The forum’s significance lies in its diverse lineup, which spans several high-interest areas of medical innovation. Sona Nanotech Inc. will present a photothermal cancer therapy built on gold nanorods, a platform that could offer targeted treatment options. Raphael Pharmaceutical brings cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease, highlighting the growing therapeutic potential of cannabinoids beyond pain management. Amplia Therapeutics Ltd. will discuss its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, a mechanism that addresses both tumor progression and tissue scarring. Adaptin Bio, Inc. focuses on precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier—a longstanding challenge in treating neurological conditions. Acurx Pharmaceuticals, Inc. is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, a critical need given rising antimicrobial resistance. CytoDyn Inc. will present a humanized monoclonal antibody being studied in solid-tumor oncology, and 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging, which could improve diagnosis and monitoring of lung diseases. Together, these presentations cover a broad spectrum of unmet medical needs, from cancer and fibrosis to drug-resistant infections and respiratory diagnostics.
For investors, the forum provides a rare chance to hear directly from management teams and ask impromptu questions. David Shapiro, Chief Executive Officer of B2i Digital, Inc., emphasized this interactive value: “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” This sentiment underscores the event’s focus on transparency and real-time dialogue, which can be more revealing than static documents.
The forum is free to attend, but registration is required. Interested parties can view event details and presenting company profiles at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum and register at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. B2i Digital, as the Official Marketing Partner, is leveraging its extensive media network—spanning over 800 outlets and a monthly audience exceeding 330 million—to amplify the event. This partnership aims to connect these companies with a broad investor base, potentially increasing visibility and investment opportunities.
The broader implications of such forums extend beyond individual company updates. They serve as a barometer for emerging trends in life sciences, such as the convergence of nanotechnology, immunotherapy, and targeted drug delivery. By featuring companies at various stages of development, the event also highlights the pipeline of potential treatments that could reach patients in the coming years. For investors, these presentations offer early insights into technologies that may shape the future of medicine, making the forum a valuable addition to any due diligence calendar.
